NCT06096870View on ClinicalTrials.gov

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Prostate CancerRecurrent Prostate CancerPET Positive
Interventions
DRUG

Enzalutamide

Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)

DRUG

PDS01ADC

PDS01ADC at 12.0 microgram/kg by subcutaneous injection (every 28 days)

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH